Canton Hathaway, LLC Tyme Technologies, Inc. Transaction History

Canton Hathaway, LLC

  • $401 Million
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

Apr 10, 2019
SELL
$1.76 - $3.73 $7,515 - $15,927
-4,270 Closed
0 $0
Q4 2018

Feb 07, 2019
BUY
$2.01 - $4.21 $8,582 - $17,976
4,270 New
4,270 $16,000

About TYME TECHNOLOGIES, INC.

TYME Quotes by TradingView
  • Ticker TYME
  • Exchange NASDAQ
  • Shares Outstandng 172,207,008
  • Description
  • Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...
More about TYME
Track This Portfolio

Track Canton Hathaway, LLC Portfolio

Follow Canton Hathaway, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Canton Hathaway, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Canton Hathaway, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email